The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...
IMFINZI was generally well tolerated ... AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a ...
Brian McNamara has a shot at beating his aggressive cancer, but his Aetna subsidiary insurance company doesn't want to pay ...
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...
Approval of Imfinzi marks the first and only perioperative immunotherapy indicated for muscle-invasive bladder cancer.
In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...
“Today’s approval for IMFINZI represents a paradigm shift, bringing the first perioperative immunotherapy to patients in the US with muscle-invasive bladder cancer and addressing a significant ...
Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...
AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback